Item 8.01 Other Events.

On September 16, 2020, Kindred Biosciences, Inc. (the "Company") issued a press release announcing positive results from its pivotal efficacy study of KIND-030, a monoclonal antibody targeting canine parvovirus. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.




Item 9.01 Financial Statements and Exhibits.
Exhibit No.                 Description
        99.1                  Press Release of Kindred Biosciences, Inc. issued on September 16,
                            2020
        104                 Cover Page Interactive Data File (embedded within the Inline XBRL
                            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses